The device was used in treatment.One 23f abiomed axillary sheath was returned.Traces of blood was found inside and outside of the sheath.The returned sheath was observed using a vertex at higher magnification and no cracks, holes or gaps were found.The sheath score lines were observed to be prominent on the outer surface.The sheath was leak tested per iso 11070 standard and procedure for leak test.Sheath leak test results did not show any leakage through the sheath score lines or the valve.Further investigation revealed that wall thickness of the scoreline has been reduce to improve the peel strength.Reduced wall thickness of the scoreline could have made the sheath susceptible to collapsing when used with graft locks, and that could have caused leakage.However, all devices that have been evaluated have met the current dimensional, visual, and functional requirements in the 23f sheath product specification.Further investigation revealed that wall thickness of the scoreline has been reduce to improve the peel strength.Reduced wall thickness of the scoreline could have made the sheath susceptible to collapsing when used with graft locks, and that could have caused leakage.However, all devices that have been evaluated have met the current dimensional, visual, and functional requirements in the 23f sheath product specification.The device history records were reviewed to confirm that the device passed all applicable in-process and final inspections.Per operations procedure(s) adelante, adelante-s and adelante-s2 sheath extrusion appropriate extrusion tool is selected for the part to be extruded and is inspected prior to the extrusion run.Peel strength and critical dimensions are verified on every 100th extruded sheath as per procedure.Per abiomed introducer sheath in-process and final sample size: 100% inspection the sheath is inspected with a naked eye at a distance of 12" to 18" to ensure the sheath is free of kinks, cracks, splits, sinks and any other damages.Leak test is performed as per procedure.Abiomed instructions for use (ifu) is provided with the product.Based on the investigation, a capa was not required.There was no new failure mode identified and the risk remains acceptable.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report isbased upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|